巴雷特食管确诊持续性低级别异型增生患者进展为肿瘤的风险增加
该多中心回顾性分析纳入255例原发性低级别异型增生(LGD)患者,由3位专家病理医师独立复核基线及后续活检标本。中位随访42个月期间45例(18%)进展为高级别异型增生(HGD)或食管腺癌(EAC);3位病理医师一致确认LGD及LGD持续存在均与进展风险显著升高相关,多灶性LGD与进展无显著关联。
要点
- 3位病理医师一致确认LGD时进展为肿瘤的比值比为47.14(95%CI 13.10-169.70)。
- 基线检出且后续内镜复查仍确认LGD时,进展比值比为9.28(95%CI 4.39-19.64)。
- 多灶性LGD与进展至肿瘤无显著关联。
核心结论
- 确认LGD的病理医师数量及LGD随时间持续存在,增加巴雷特食管LGD患者进展为HGD或EAC的风险。
研究设计与样本
- 对欧洲一项比较监测与射频消融的随机对照试验中255例原发性LGD患者(78%为男性,平均年龄63岁)的数据进行回顾性分析。
- 由3位专家病理医师独立复核基线与后续LGD标本,按维也纳分类系统分别记录每份活检的异型增生有无及程度,主要终点为发生HGD或EAC。
主要发现
- 255例患者中45例(18%)在中位42个月随访期(四分位距25-61个月)内进展为HGD或EAC,患者接受中位4次内镜检查(四分位距3-6次)。
- 3位病理医师一致确认LGD时进展风险大幅升高,比值比47.14(95%CI 13.10-169.70)。
- 基线检出LGD且后续内镜复查确认时,进展比值比9.28(95%CI 4.39-19.64)。
- 多灶性LGD与进展至肿瘤无显著关联。
临床怎么用
- 作者认为,确认LGD的病理医师数量与LGD持续存在这两个简单易得的变量有助于风险分层并选择患者接受预防性消融治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: For patients with Barrett's esophagus, the diagnosis of low-grade dysplasia (LGD) is subjective, and reported outcomes vary. We analyzed data from a multicenter study of endoscopic therapy to identify factors associated with progression to high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC) in patients with LGD of the esophagus. METHODS: We performed a retrospective analysis of data from 255 patients with a primary diagnosis of LGD (78% men; mean age, 63 years) who participated in a randomized controlled trial of surveillance vs radiofrequency ablation in Europe. Three expert pathologists independently reviewed baseline and subsequent LGD specimens. The presence and degree of dysplasia was separately recorded for each biopsy and classified according to the Vienna Classification system. The primary end point was development of HGD or EAC. We performed univariate logistic regression analyses to assess the association between outcomes and factors such as number of pathologists confirming LGD, multifocality of LGD, and persistence of LGD over time. RESULTS: Of the 255 patients, 45 (18%) developed HGD or EAC during a median 42-month follow-up period (interquartile range, 25-61 months); patients were examined by a median 4 endoscopies (interquartile range, 3-6 endoscopies). The number of pathologists confirming LGD was strongly associated with progression to neoplasia; risk for progression increased greatly when all 3 pathologists agreed on LGD (odds ratio, 47.14; 95% confidence interval, 13.10-169.70). When LGD was detected at baseline and confirmed by a subsequent endoscopy, the odds for progression to neoplasia also increased greatly (odds ratio, 9.28; 95% confidence interval, 4.39-19.64). Multifocal LGD was not significantly associated with progression to neoplasia. CONCLUSIONS: The number of pathologists confirming LGD and persistence of LGD over time increase risk for development of HGD or EAC in patients with Barrett's esophagus and LGD. These simple, readily available variables can help stratify risk and select patients for prophylactic ablation therapy.
引用
- Duits LC, van der Wel MJ, Cotton CC, et al. Patients With Barrett's Esophagus and Confirmed Persistent Low-Grade Dysplasia Are at Increased Risk for Progression to Neoplasia. Gastroenterology. 2016. PMID: 28012849. doi:10.1053/j.gastro.2016.12.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。